New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma
Official title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
Funded at Marker Therapeutics, INC. · NIH-10922163 · Data updated 2026-11-12
This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marker Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $665,000 |
| NIH project number | 1R44CA291521-01 |
| Project ID | NIH-10922163 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with relapsed Non-Hodgkin Lymphoma who have previously undergone CAR T cell therapy and are seeking new treatment options.
✕Less likely to help
Patients with Non-Hodgkin Lymphoma who have not relapsed or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates a novel treatment using patient-derived T cells that target multiple tumor-associated antigens in individuals with relapsed Non-Hodgkin Lymphoma (NHL). The approach involves collecting a patient's own immune cells through a process called apheresis, which are then modified to recognize and attack cancer cells expressing specific antigens. By targeting multiple antigens simultaneously, this therapy aims to improve the effectiveness of treatment and reduce the chances of cancer relapse. Patients will be closely monitored for safety and effectiveness throughout the treatment process.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with relapsed Non-Hodgkin Lymphoma who currently have limited alternatives.
How similar studies have gone: While CAR T cell therapies have shown success in treating NHL, this approach of targeting multiple tumor-associated antigens is relatively novel and has not been widely tested.
Where this research is happening
-
Marker Therapeutics, INC.
Houston, United States Active
Researchers
- Principal investigator: Vera, Juan Fernando — Marker Therapeutics, INC.
- Study coordinator: Vera, Juan Fernando
Related research
Other NIH-funded projects on the same topics.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma
This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.